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InfectivityThe Epstein-Barr virus (EBV) BGLF4 gene product is the only protein kinase encoded by the virus genome. In
order to elucidate its physiological roles in viral productive replication, we here established a BGLF4-
knockout mutant and a revertant virus. While the levels of viral DNA replication of the deﬁcient mutant were
equivalent to those of the wild-type and the revertant, virus production was signiﬁcantly impaired.
Expression of the BGLF4 protein in trans fully complemented the low yield of the mutant virus, while
expression of a kinase-dead (K102I) form of the protein failed to restore the virus titer. These results
demonstrate that BGLF4 plays a signiﬁcant role in production of infectious viruses and that the kinase activity
is crucial.
© 2009 Elsevier Inc. All rights reserved.IntroductionThe Epstein-Barr virus (EBV) is a human gamma-herpesvirus that
is present in most of the world's population. Upon infection, it
predominantly establishes a latent infection in B lymphocytes and a
limited number of viral proteins are expressed. Only a small
percentage of infected cells switch from a latent stage of infection
into the lytic cycle when a number of viral proteins are expressed,
leading to production of progeny viruses (Tsurumi et al.,2005). Among
them, the EBV BGLF4 gene product is the only protein kinase (Polack
et al., 1996) identiﬁed in the virus genome. Previous studies have
identiﬁed several viral gene products as targets of the kinase,
including BMRF1 (EA-D, DNA polymerase processivity factor) (Chen
et al., 2000), BZLF1 (Zta, b-Zip transcription factor) (Asai et al., 2006),
EBNA-LP (Kato et al., 2003), EBNA-2 (Yue et al.,2005) and even BGLF4
itself (Chen et al., 2000). The PK also phosphorylates cellular proteins;
translation elongation factor 1 (Kato et al., 2001) casein kinase II
(Kawaguchi et al., 2003) andminichromosomemaintenance (MCM) 4
and 6 (Kudoh et al., 2006). Judging from the phosphate acceptor
residues and their vicinities, the kinase targets phosphorylate serin/
threonine residues similarly to Cdc2 (Kawaguchi and Kato, 2003).ncer Center Research Institute,
ax: +81-52-764-2979.
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families and the gene products phosphorylate common cellular/viral
targets (Kawaguchi and Kato, 2003). Deﬁciency of the UL13 gene, the
homologue in herpes simplex virus (HSV), reduces expression levels
of an immediate early (IE) gene ICP0 and some late genes, including
UL26, UL38, UL41 and US11, thereby impairing the capacity to
replicate in some cell lines (Ng et al., 1997; Ogle and Roizman, 1999;
Purves, Ogle, and Roizman, 1993). HSV-1 UL13 PK is a virion
component (Overton et al., 1992). It phosphorylates structural
components of virus particles, and promotes dissociation of tegument
proteins upon infection into naive cells (Morrison et al., 1998).
Another homologue, human cytomegalovirus (HCMV) UL97 kinase, is
also a component of the virion particle (van Zeijl et al., 1997), and it
affects viral DNA replication, encapsidation and nuclear egress
(Krosky et al., 2003; Wolf et al., 2001). With EBV, Gershburg et al.
(2007) recently showed, using small interfering RNA technology, that
BGLF4 protein is involved in the production of infectious virus
particles. In addition, the BGLF4 gene product is detected in the
tegument portion of the virus particle (Wang et al., 2005), like other
homologues. These reports suggested that BGLF4 PK plays a role in the
virus particle formation or infectivity. Despite intensive studies,
however, the physiological role of the BGLF4 PK has hitherto not
been conﬁrmed due to the lack of a BGLF4 null mutant virus.
We therefore established BGLF4 knockout mutants for comparison
with the wild-type and rescued isolates. The deﬁcient viruses showed
markedly reduced levels of progeny virus production, although viral
DNA replication levels were not affected. Expression of BGLF4 kinase
76 T. Murata et al. / Virology 389 (2009) 75–81in trans restored the virus yield, while a kinase-dead form lacked the
activity. These results strongly suggest that the reduction in yield with
the knockout mutant is not due to a lack of the virion component but
rather that the kinase activity of the BGLF4 gene product plays an
important role in virus maturation during virus lytic infection.
Results
Construction of recombinant viruses
To analyze biological functions of the BGLF4 gene, we ﬁrst
constructed BGLF4-deﬁcient recombinant viruses, dBGLF4/Kan and
dBGLF4/FRT, as shown in Fig. 1A. The marker cassette containing the
kanamycin-resistance gene, ﬂanked by the FRT sequence, was inserted
into nt251 to 320, to construct dBGLF4/Kan. We inserted the cassette
here because the nt251–320 of the gene contains the catalytic domain
including the K102 residue (nt304–306), which is crucial for
enzymatic activity (Kato et al., 2003). To make dBGLF4/FRT, we then
removed the kanamycin cassette from dBGLF4/Kan using the FLP
recombinase, leaving only the 34-bp FRT sequence. Because of the 34
nucleotides left in the construct, the gene cannot be produced in
frame, indicating that the virus is still devoid of the BGLF4 kinase.
A different cassette was used to create another deﬁcient mutant
(dBGLF4/NeoSt) and its revertant (dBGLF4/NeoSt/R) (Fig. 1B). The
marker cassette containing the neomycin-resistance gene and the
streptomycin-sensitivity gene was inserted into nt251 to 320, to
construct dBGLF4/NeoSt. Then the cassette was replaced with a wild-
type BGLF4 sequence to prepare the revertant virus, dBGLF4/NeoSt/R.
Streptomycin selection was carried out to eliminate the viral genome
that was not switched with the wild-type BGLF4 sequence.
These recombinant EBV genomes were analyzed by BamHI
digestion, followed by agarose gel electrophoresis (Fig. 1C). The
BamHI-G fragment is present in wild-type and revertant (dBGLF4/
NeoSt/R) viruses (white arrowhead), but the corresponding bands of
dBGLF4/Kan and dBGLF4/NeoSt viruses migrated slowly in the gel by
about 1.3 and 1.8 kb (Fig. 1C, ⁎ and N), respectively, which are the sizes
of the cassettes. The digestion pattern of dBGLF4/FRT was almost
identical to that of the wild-type, because the difference is only 34 bp,
as detailed above.
The recombinant EBVDNAswere introduced intoHEK293 cells, and
hygromycin-resistant cell colonies were cloned for further analysis.
Screeningwas doneby immunoblotting analysis todeterminewhether
lytic infection could be induced by exogenous expression of BZLF1.
More than 3 successful colonies from each virus were collected and
analyzed. In the following part of this manuscript, we show data using
one typical clone for each recombinant virus.
Viral protein expression with BGLF4-deﬁcient viruses
In order to characterize the recombinant viruses, expression of
lytic viral proteins was determined by immunoblotting (Fig. 2).
Proteins were prepared from the HEK293 cells containing theFig. 1. Recombinant EBV BAC genome structures. (A) Schematic arrangement of the
recombination of the EBV genome using the kanamycin-resistance gene and FLP/FRT
recombination. The region between nucleotide 251 to 320 of the BGLF4 gene was
replaced with the kanamycin-resistance gene (Kan), ﬂanked by the FRT sequence, to
create dBGLF4/Kan. The kanamycin-resistance gene was excised by FLP-mediated
recombination to construct dBGLF4/FRT. (B) Schematic arrangement of the recombi-
nation of the EBV genome using the neomycin-resistance and streptomycin-sensitivity
genes. The region between nucleotide 251 and 320 of the BGLF4 gene was replaced
with the tandemly arranged neomycin-resistance and streptomycin-sensitivity (St+)
genes to make dBGLF4/NeoSt. The NeoSt+cassette was then replaced with a wild-
type BGLF4 sequence to construct the revertant virus dBGLF4/NeoSt/R. (C)
Electrophoresis of the recombinant viruses. EBV BAC DNAs were digested with
BamHI and separated in an agarose gel. The white arrowhead indicates the BamHI-G
fragment of the virus, ⁎ and N indicate the sizes of BamHI-G fragments plus the
marker cassettes.indicated recombinant EBV genome, at various hours after transfec-
tion, with the expression vector for BZLF1. Copious amounts of the
BZLF1 protein were detected in both cell lines from 12 h, indicating
successful transfection.
Expression of the BGLF4 protein is detected only in wild-type and
dBGLF4/NeoSt/R, the revertant virus, as expected.
It has been reported that the BMRF1 protein is phosphorylated by
BGLF4 PK and that its mobility in SDS-PAGE gels reﬂects its
phosphorylation status (Tsurumi, 1993; Yang et al., 2008). The major
band of BMRF1 protein fromwild-type and dBGLF4/NeoSt/R migrated
Fig. 2. Viral protein expression in wild-type, BGLF4-knockout, and revertant viruses. HEK293cells, latently infected with the indicated EBV genomes, were transfected with the
BZLF1 expression vector, and harvested at various time points thereafter. Immunoblotting was carried out with anti-BMRF1, -BZLF1, -BALF2, -BGLF4, -BALF5, and -gB (BALF4, also
termed gp110) antibodies. The CBB (Coomassie Brilliant Blue) staining pattern is shown as a loading control. N indicates the most heavily phosphorylated major band of BMRF1 in
the wild-type virus.
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form. On the other hand, all BGLF4-deﬁcient viruses, dBGLF4/NeoSt,
dBGLF4/Kan and dBGLF4/FRT, showed several bands migrating faster
than the major band with the wild-type virus. Taking into account that
the BMRF1 protein is also targeted by cellular kinase(s) (Yang et al.,
2008), we concluded that BGLF4 PK was knocked out as expected in
dBGLF4/NeoSt, dBGLF4/Kan and dBGLF4/FRT, while the kinase was
intact and functional in wild-type and dBGLF4/NeoSt/R.
Expression levels of viral early genes including BMRF1, BALF2,
BALF5 were low at 12 h and became evident at 24 h or afterward.
BALF4, encoding gB (also termed glycoprotein 110), was expressed
somewhat later than the early genes. For better comparison, protein
levels of the recombinant viruses were checked in Fig. S1. The
expression levels and kinetics of these gene products were quiteFig. 3. Viral DNA synthesis in BGLF4-deﬁcient viruses. (A) HEK293cells with the indicated EBV
points after transfection. As a control, 100,10,1, 0.1, 0.01 ng of EBV BAC DNA puriﬁed from E. co
by dot blot assay as described in the Materials and methods. (B) The radioactivities were q
triangle, dBGLF4/NeoSt; diamond, dBGLF4/FRT.similar and indistinguishable among the wild-type, knockout and
revertant viruses. The levels of transcripts of some other late genes
including BLLF1 (gp350), BBRF3 (glycoprotein M), and BcLF1 (major
capsid protein), were also indistinguishable among the viruses as
judged by RT-PCR (data not shown). The results indicate that
knockout of BGLF4 gene does not greatly affect expression of, at
least, several genes.
Viral DNA synthesis in BGLF4-deﬁcient viruses
We next checked the levels of viral DNA synthesis in HEK293
cells with the wild-type and recombinant viruses. Dot blot
hybridization analysis demonstrated that DNA copy numbers of
BGLF4 PK-deﬁcient viruses increased just like those of wild-type orgenomes were transfectedwith BZLF1 expression vector, and harvested at various time
liwas also blotted at the top of the panel. Levels of viral DNA synthesis were determined
uantiﬁed and plotted. Circle, wild-type; asterisk, dBGLF4/NeoSt/R; box, dBGLF4/Kan;
Fig. 4. Reduced yield of BGLF4-deﬁcient viruses. HEK293cells carrying the indicated EBV
genomes were transfected with BZLF1 expression vector, and harvested at various days
after transfection. After freezing/thawing and centrifugation, the supernatants were co-
cultured with Akata(−) cells. GFP-positive cells were counted by FACS. Circle, wild-
type; asterisk, dBGLF4/NeoSt/R; box, dBGLF4/Kan; triangle, dBGLF4/NeoSt; diamond,
dBGLF4/FRT.
Table 1
Infectious particles produced from cells.
GFP-positive cells (%)
Medium Cell-associated
dBGLF4/Kan/FRT 1.3 0.9
dBGLF4/Kan 1.1 1.8
Wild-type 6 5.6
dBGLF4/NeoSt 1.2 1.2
dBGLF4/NeoSt/R 8.2 7.1
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DNA synthesis of the EBV genome.
Reduced production of BGLF4-deﬁcient viruses
To determine the yields of the viruses, HEK293 cells carrying each
EBV BAC clone were transfected with the BZLF1 expression vector to
induce lytic replication and harvested together with culture medium
at various days after transfection, followed by freezing and thawing.
After centrifugation to clear the cell debris, the supernatants were co-
cultured with EBV negative Akata cells (Akata(−)) and applied for
FACS analysis. Since the recombinant EBV expresses GFP protein,
Akata(−) cells infected with the virus become GFP-positive (Dele-
cluse et al., 1998). On the fourth day after BZLF1 transfection, GFP-
positive cells infected with wild-type and the revertant viruses
reached 4.0% and 6.4% of the total cells, while GFP-positive cells
with BGLF4-deﬁcient viruses on day 4 accounted for only 0.37, 0.74
and 0.61% (Fig. 4). To extend this experiment, furthermore, viral titers
associated with the HEK293 cells and with the medium were
quantiﬁed independently (Table 1). Both cell-associated and medium
virus titers of wild-type and the revertant were signiﬁcantly higher
than those of BGLF4-deﬁcient viruses. These results support the
previous report (Gershburg et al., 2007) that BGLF4 PK is involved in
production of infectious viruses.
Trans complementation of the reduced infectivity of BGLF4-deﬁcient
viruses
Because the comparisons were performed using isolated HEK293
clones, the possibility remained that the results were due to individual
variation in selected clones. We therefore tested whether expression
of BGLF4 PK in trans could restore the reduced virus yield. Without
any exogenous supply of BGLF4 (Fig. 5A, gray bars), the knockout
viruses showed signiﬁcantly lower virus production than the wild-
type and revertant. When Flag-tagged BGLF4 PK was transfected (Fig.
5A, black bars), the virus titer increased as to the same level of
infectious particles as with the wild-type and revertant. Exogenous
expression of PK with the wild-type or revertant viruses did not
improve the virus titer, suggesting the increase in infectious virus
yield by introduction of BGLF4 in trans to be speciﬁc. In contrast, with
transfection of kinase-dead form of BGLF4 expression vector, recovery
of production of infectious virus was lacking (Fig. 5A, white bars).
Immunoblotting analysis indicated that endogenous and exogenous
BGLF4 was expressed as expected and that the K102I mutant of BGLF4
was devoid of kinase activity because BMRF1 phosphorylation levels
remained low (Fig. 5B).Discussion
In this study, we generated recombinant EBV devoid of BGLF4 PK
and one rescued virus, and thereby conﬁrmed that the kinase is
involved in production of infectious viruses. This is in line with the
previous report by Gershburg et al. (2007), documenting knock down
of the BGLF4 gene by RNA interference (RNAi). Silencing of genes by
RNAi has become an effective tool in biological research, but there are
weaknesses, too. As the silencing efﬁciency is not 100%, there is always
remnant target gene product, and there might be residual enzyme
activity if the target is a kinase. Another weakness is that RNAi might
affect surrounding genes if one mRNA covers more than one gene.
BGLF4, BGLF3, BGLF5 and BBLF1 transcripts are presumed to share the
same mRNAs (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene
and Cmd=retrieve and dopt=full_report and list_uids=3783704 and
log $=databasead and logdbfrom=nuccore). Also, off-target effects of
an RNAi on genes sharing very similar sequences to the target might
not be negligible. Because of these weaknesses, knockout of virus
genes by recombination is still an effective means to analyze
functions. Gershburg et al. (2007) showed that BGLF4 knockdown
slightly reduced viral DNA replication and partially inhibited expres-
sion of some viral genes. Here, in contrast, we observed little or no
reduction in viral DNA replication and gene expression, although the
phosphorylation state of the BMRF1 polymerase accessory protein
totally differed. These marginal discrepancies may be explained by
differences in approaches to eliminating the gene product.
Since BGLF4 PK is a component of EBV viral particles (Wang et al.,
2005), it is of great interest whether the presence of the protein
molecule, even without the kinase activity, is sufﬁcient to recover
virus production. We therefore carried out trans complementation
assay and clearly demonstrated that the kinase activity of BGLF4 is
essential for maturation of virus progeny (Fig. 5). Relevant to this
result is Tanaka's report (Tanaka et al., 2005) that recombinant virus
expressing enzymatically inactive HSVUL13 PK formed smaller
plaques and yielded a 10-fold reduction in progeny as compared to
the wild-type virus.
It has been suggested that BGLF4 PK acts in replicating cells at the
steps of viral gene expression, DNA replication, nuclear alteration and
nuclear egress (Gershburg et al., 2007; Kudoh et al., 2006; Lee et al.,
2007; Lee et al., 2008; Tarakanova et al., 2007; Yang et al., 2008). Our
electron microscopy data indicates that the majority of viral capsids
were detected in the nucleus of cells with BGLF4-deﬁcient virus,
whereas particles were found both in the nucleus and cytoplasm in
cells carrying the revertant EBV genome (data not shown). Therefore,
the PK most likely and signiﬁcantly functions at the step of nuclear
egress. This result is in agreement with the result of HCMV homolog of
EBV BGLF4 PK (Krosky et al., 2003). As for HSV, it has been known that
re-localization of UL31/34 gene products onto the nuclear membrane
is critical for nuclear egress of the virus, and that US3 PK is required for
the UL31/34 re-localization (Reynolds et al., 2001). Involvement of
UL13 PK, the BGLF4 homolog, on the process is also reported (Kato
et al., 2006). Because EBV does not encode homologous gene to HSV
US3, it is likely that this hypothesis for HSV is not applicable as it is.
Although Lake and Hutt-Fletcher (2004) reported that distributions
and phosphorylation status of the BFLF2/BFRF1, homologs of the HSV
Fig. 5. Trans complementation of reduced production of BGLF4-knockout viruses. (A) HEK293cells carrying the indicated EBV genomes were transfected with the BZLF1 expression
vector, together with the Flag-taggedwild-type (wt, black bars), the kinase-dead (KI, white bars) mutant of BGLF4 or its empty vector (vector, gray bars). Four days after transfection,
samples were harvested and infected into Akata(−) cells, followed by FACS analysis. (B) Expression levels of exogenous and endogenous BGLF4, BZLF1 and BMRF1 proteins in (A),
measured by immunoblotting.
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showed that BGLF4 PK phosphorylates lamin A/C to promote
reorganization of nuclear inner membrane, which in turn may
facilitate the BFLF2 and BFRF1 interaction, thereby enhancing virion
maturation. The precise mechanism of how BGLF4 PK enhances
nuclear egress still remains controversial, but is currently being
examined using our knockout viruses.
In summary, development of BGLF4 knockout and revertant viruses
here allowed conﬁrmation of the importance of enzymatic activity of
EBV BGLF4 PK for infectious virus production. To clarify the target
substrate(s) of BGLF4 PK that signiﬁcantly affects the viral infectivity is
our next aim. Our recombinant viruses, including BGLF4 knockout and
the revertant strain, together with trans complementation system can
obviously serve as a useful tool for that purpose.
Materials and methods
Cell culture and reagents
HEK293 cells or its derivatives were maintained in Dulbecco's
modiﬁed Eagle medium (Gibco BRL) supplemented with 10% fetal
bovine serum. Akata(−) cells were cultured in RPMI1640 medium
containing 10% fetal bovine serum. Mouse anti-FLAG antibody was
from Sigma. Horseradish peroxidase-linked goat antibodies to mouse
or rabbit IgG were from Amersham Biosciences. Antibodies against
BZLF1, BGLF4, BMRF1, BALF2, BALF5, BALF4 were as reported earlier
(Daikoku et al., 2006; Kanda et al., 2004; Kato et al., 2001; Kudoh et al.,
2003; Tsurumi et al., 1993).
Plasmid construction
The expression vector for BZLF1, pcDNABZLF1, was generated by
cloning the BZLF1 gene into pcDNA3 at BamHI and XhoI sites. To
prepare the expression vector for BGLF4, pcDNAFlagBGLF4, the BGLF4
sequence was cloned into EcoRI and XbaI sites of pcDNA3 with a Flag
tag. Primers used for BGLF4 ampliﬁcation were: 5′-CAGTGAATTC-
ATGGATGTGAATATGGCTGC-3′ (forward), 5′-ATACTCTAGATCATCCAC-
GTCGGCCATCTG-3′ (reverse). A point mutation (K102I) in the BGLF4
expression vector was introduced by PCR using the following primers:
5′-ACTCTATGACTCTGTGACGG-3′ (forward), 5′-ATGACCGTGGCATTA-
TCTGC-3′ (reverse).Genetic manipulation of EBV-Bac DNA
EBV-Bac DNA was provided by W. Hammerschmidt (Delecluse et
al., 1998). Homologous recombination was carried out in E. coli as
described previously (Isomura et al., 2008; Isomura et al., 2004).
For the ﬂippase (FLP)/FLP recombination target (FRT) system, we
prepared DNAs for recombination containing a kanamycin-resistance
gene ﬂanked by the 34-bp minimal FRT sequence and sequences
homologous to viral DNA, using the following primers; 5′-gccgtgg-
ccttcccaatctgaatcatgtcacacaccatgagctcgtgatacagctccGAAGTTCC-
TATTCTCTAGAAAGTATAGGAACTTCaactcagcaaaagttcgatttattcaac-3′
(forward) and 5′-taaagctgccggagaacatgacgcgctgtgatcacctccccat-
tacctgcgagtatctgcGAAGTTCCTATACTTTCTAGAGAATAGGAACTTCtaatg-
ctctgccagtgttacaacca-3′ (reverse).
To obtain revertant virus, the kanamycin resistance gene and the
streptomycin sensitivity gene in the PpsL-neo (Gene Bridges,
Germany) were employed. DNA fragments for recombination were
generated by PCR with the following primers; 5′-gccgtggccttcccaatct-
gaatcatgtcacacaccatgagctcgtgatacagctccgtcGGCCTGGTGAT-
GATGGCGGGATC-3′ (forward) and 5′-taaagctgccggagaacat-
gacgcgctgtgatcacctccccattacctgcgagtatctgcTCAGAAGAACTCGTCAA-
GAAGG-3′ (reverse). Revertant viruses were made using the PCR
fragment ampliﬁed by the following primers; 5′-TAGTCCACCA-
GGGCCTTGTC-3′ (forward) and 5′-ACATTGATGACATGACGGAG-3′
(reverse).
Electroporationwas performed using Gene Pulser III (Bio-Ran) and
puriﬁcation of EBV-Bac DNA was achieved with NucleoBond Bac100
(Macherey-Nagel, Germany).
Transfection, cell cloning and immunoblotting
EBV-BacDNA was transfected into HEK293 cells using lipofecta-
mine 2000 reagent (Invitrogen) or a Microporator (Digital Bio). After
transfection of Bac DNA, cells were cultured on 10 cm dishes with
100 μg/ml of hygromycin B for 10–15 days and GFP-positive cell
colonies were cloned as described previously (Murata et al., 2009).
Shortly, for each recombinant virus, we picked up more than 10
hygromycin-resistant, GFP-positive cell colonies to obtain at least 3
typical clones that exhibit minimal spontaneous expression of viral
lytic proteins, and signiﬁcant induction of them upon BZLF1
transfection.
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were transfected with 100 ng or 200 ng of pcDNABZLF1 using
lipofectamine 2000 reagent (Invitrogen) or the Microporator (Digital
Bio) to induce a virus lytic cycle. At various times after transfection,
cells were washed with PBS and harvested for immunoblotting (IB) as
described previously (Murata and Shimotohno, 2006).
Quantiﬁcation of viral DNA synthesis during lytic replication
Levels of viral DNA were determined by Dot-blot hybridization as
described previously (Kudoh et al., 2003). HEK293 cells with latently
infected EBV genome were harvested at the indicated time points.
Total DNAs were puriﬁed from 106 cells by phenol-chloroform
treatment and ethanol precipitation, followed by quantiﬁcation.
Equal amounts of DNA samples (500 ng) were dot blotted on a
hybond-N membrane (Amersham) and hybridized with a 32P-labeled
DNA probe. The signal intensity was quantiﬁed with an Image Guider
(BAS2500, Fuji Film), and a standard curve for viral DNA quantiﬁcation
was obtained from serial dilutions of EBV BAC DNA, where signal
intensities do not reach a plateau.
FACS analysis
Akata cells were ﬁxedwith 1% formaldehyde, washedwith PBS and
suspended in PBS. GFP-positive cells were counted using the FACS
Calibur G5 system (Becton-Dickinson), according to the manufac-
turer's instructions.
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